Mark C. McKenna - 01 Feb 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRE	Stock Option (Right to Buy)	Award	$0	+40,000		$0.000000	40,000	01 Feb 2024	Common Stock	40,000	$25.86	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This option represents a right to purchase 40,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on February 1, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.